Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.57 |
| ▸ | PPARA | Q07869 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18949031 | 0.98 | GRIA1 (0.54) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL10147477 | 0.92 | CA1 (0.54) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL12232575 | 0.84 | GRIA1 (0.57) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL13959008 | 0.83 | GRIA1 (0.83) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL20734509 | 0.83 | GRIA1 (0.83) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL24735803 | 0.83 | GRIA1 (0.83) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL19996862 | 0.83 | GRIA1 (0.42) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL12988696 | 0.83 | CA1 (0.50) | GRIA1PPARACA2CA1CA12 | |
| SCHEMBL14654996 | 0.81 | GRIA1 (0.78) | GRIA1PPARACA2CA1EPHX1 | |
| SCHEMBL7691833 | 0.81 | PPARA (0.64) | PPARACA2CA1EPHX1RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | GRIA1 4165/4885PPARA 1718/4885CA2 3176/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | GRIA1 4165/4885PPARA 1718/4885CA2 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.